DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457 for Human Papillomavirus

"A score of two was assigned to DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457 due its Phase 2 status, which implies a moderate degree of safety data exists but no proof that it is effective."

"At this juncture, the clinical trial is not actively enrolling. The original posting was on November 14th 2018 and has been edited as recently as February 11th 2022. For those interested in other studies, there are 5656 trials for relapse recruitment and 340 active trials related to MEDI0457 DNA Plasmid-encoding Interleukin-12/HPV Therapeutic Vaccine currently recruiting patients."

"Patients with unresectable stage III non-small cell lung cancer can benefit from the use of DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457. This therapeutic vaccine has also proven useful in treating previously untreated metastatic ureter urothelial carcinoma and advanced directives."

"This clinical trial is no longer accepting participants as it has reached the end of its recruitment period. It was initially posted on November 14th 2018 and last edited on February 11th 2022. Other studies that may be applicable can be found, with 5656 trials actively enrolling patients for relapse and 340 seeking those eligible for MEDI0457's DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine therapy."

"Currently, 340 clinical trials are underway to study the efficacy of DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457. Of these studies, 52 have advanced to Phase 3. While most facilities running tests for this vaccine can be found in Cordoba, Texas; 13003 sites across the world are participating in related research."